Evidence map›Paper›PMID 30710809›Full record

ArticlePsychiatry research2019

The nature of bradykinesia in schizophrenia treated with antipsychotics.

Michael P Caligiuri, Hans-Leo Teulings, Charles E Dean, James B Lohr

Abstract read
In one paragraph

Article in Psychiatry research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Patterns of Impaired Neurocognitive Performance on the Global Neuropsychological Assessment, and Their Brain Structural Correlates in Recent-onset and Chronic Schizophrenia.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2023
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Michael P CaligiuriUniversity of California, San Diego, CA, United States. Electronic address: mcaligiuri@ucsd.edu.
Hans-Leo TeulingsNeuroScript LLC, Tempe AZ, United States.
Charles E DeanMinneapolis VA, Minneapolis MN, United States.
James B LohrUniversity of California, San Diego, CA, United States; VA San Diego, Center of Excellence for Stress and Mental Health.
University of California San Diego · USMinneapolis VA Medical Center · USNeuroscript (United States) · US

Funding

Movement Analysis to Monitor Medication Side EffectsR44MH073192 · NIMH · NEUROSCRIPT, LLC · PI TEULINGS, HANS-LEO · 2006 to 2007
$751k
NIMH NIH HHS R44 MH073192
6 · The paper itself

Abstract

Recognizing drug-induced parkinsonian bradykinesia in psychosis patients can be challenging due to overlapping presentation with psychomotor slowing associated with depression, negative symptoms, or cognitive disturbances. In this study, we apply prior findings on the pathophysiology of bradykinesia in Parkinson's disease to gain an understanding of motor slowing in psychosis patients. Handwriting movements from 57 healthy participants and 70 psychosis patients were recorded on a digitizing tablet. Temporal and kinematic features were extracted from handwritten loops and circles. An independent objective measure based on peak velocity for circles written at maximum speed was used to classify patients as bradykinetic. Using a statistical cut-point derived from normative data, 64% of the patients met criterion for bradykinesia compared with 46% using a conventional observer-based severity rating scale. Bradykinetic patients produced handwriting movements with longer stroke durations, smaller amplitudes and lower peak velocities compared with non-bradykinetic patients. Thirty-six percent of the pen strokes produced by the bradykinetic patients were non-ballistic compare with 20% for the non-bradykinetic patients. The proportion of nonballistic movements observed in handwriting was unrelated to current antipsychotic dose, severity of negative psychosis or depression. The ease-of-use and standardization of a tablet-based approach to quantifying parkinsonian bradykinesia can aid in diagnosing parkinsonian bradykinesia in patients treated with antipsychotics.

Indexed as

HandwritingAdultAntipsychotic AgentsFemaleHumansHypokinesiaMaleMiddle AgedMovementParkinson DiseaseSchizophreniaTreatment OutcomeAntipsychotic Agents

Identifiers

PMID30710809
PMCPMC6561794
OpenAlexW2910765281

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.